Last update 31 May 2025

MH-048

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MH048
Target
BTK C481S
Action
inhibitors
Mechanism
BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors)
Therapeutic Areas
Immune System DiseasesHemic and Lymphatic Diseases
Active Indication
B-Cell Malignant Neoplasm
Inactive Indication-
Originator Organization
Minghui Pharmaceutical (Shanghai) Co., Ltd.
Active Organization
Minghui Pharmaceutical (Shanghai) Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with MH-048
CTR20220700
/ RecruitingPhase 2
MH048 用于复发/难治性 B 细胞恶性肿瘤患者的安全性、药代动力学以及抗肿瘤药效的多中 心、开放标签、剂量递增及队列扩展 Ⅰ/Ⅱ 期临床研究
[Translation] A multicenter, open-label, dose-escalation and cohort expansion Phase I/II clinical study of the safety, pharmacokinetics and antitumor efficacy of MH048 in patients with relapsed/refractory B-cell malignancies
NCT04689308
/ Unknown statusPhase 1
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of MH048 in Subjects With Selected Relapsed/Refractory B-cell Malignancies
100 Clinical Results associated with MH-048
Login to view more data
100 Translational Medicine associated with MH-048
Login to view more data
100 Patents (Medical) associated with MH-048
Login to view more data
1
Literatures (Medical) associated with MH-048
01 Jan 2005Medicina (Kaunas, Lithuania)Q4 · MEDICINE
New xanthone derivatives as potent anti-inflammatory agents.
Q4 · MEDICINE
100 Deals associated with MH-048
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell Malignant NeoplasmPhase 2
China
Minghui Pharmaceutical (Shanghai) Co., Ltd.
07 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04689308 (ASCO2022)
ManualManual
Phase 1
Chronic Lymphocytic Leukemia
12
xercptwrcq(jytthmqygy) = Drug-related grade 3 TEAEs included platelet count decrease, neutrophil count decrease, lipase increase, and hypertension (one patient for each). xlusnuvtwx (jilhhzkokg )
View more
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free